Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression - Major Depressive Disorder
Phase NA
Enrollment 225
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to examine attentional biases for facial displays of emotion as a mechanism of risk in infants of mothers with postpartum major depression, and the potential role of infant arousal in the development of these attentional biases.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Passive Viewing Task — Infants will complete a computer-based task in which they view facial displays of emotion (angry, happy, sad, neutral) while an eye tracker records their gaze.
  • Other: Interaction Task — Mother and infants will also complete a standardized interaction task during which we assess infant gaze and psychophysiology. The task consists of three stages, each of which lasts three minutes. For the first stage (Free Play 1), infants sit in a highchair and mothers are asked to play with their baby as they normally would, without any toys or other objects. In the second stage (Sad), mothers are asked to think about times when they are sad or depressed and do not feel able to effectively play with their child. They are instructed to look at their child but speak in a monotone and minimize body movement or any physical contact with the infant. In the third stage (Free Play 2), mothers again interact with their infants normally for three minutes.

Primary Outcomes

  • Eye gaze during computer-based task (Baseline and 3-, 6-, 9-, and 12-month follow-up)
  • Eye gaze during the interaction task (Baseline and 3-, 6-, 9-, and 12-month follow-up)
  • Infant Heart Rate (Baseline and 3-, 6-, 9-, and 12-month follow-up)
  • Infant Respiratory Sinus Arrhythmia (Baseline and 3-, 6-, 9-, and 12-month follow ups)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-14
Completion: 2029-07
Eligibility
Age: 6 Months and older
Sex: ALL
Volunteers: true
Enrollment: 225 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Binghamton University
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Brandon E Gibb, Ph.D.
607-777-2511
bgibb@binghamton.edu
Brandon E Gibb, Ph.D.
607-777-2511
bgibb@binghamton.edu
Binghamton University
Brandon E Gibb, Ph.D.
Binghamton University
Interventions
  • Other: Passive Viewing Task — Infants will complete a computer-based task in which they view facial displays of emotion (angry, happy, sad, neutral) while an eye tracker records their gaze.
  • Other: Interaction Task — Mother and infants will also complete a standardized interaction task during which we assess infant gaze and psychophysiology. The task consists of three stages, each of which lasts three minutes. For the first stage (Free Play 1), infants sit in a highchair and mothers are asked to play with their baby as they normally would, without any toys or other objects. In the second stage (Sad), mothers are asked to think about times when they are sad or depressed and do not feel able to effectively play with their child. They are instructed to look at their child but speak in a monotone and minimize body movement or any physical contact with the infant. In the third stage (Free Play 2), mothers again interact with their infants normally for three minutes.
Study Locations (1 sites)
Binghamton University, Binghamton, New York 13902 United States
Eligibility Criteria
Inclusion Criteria: * The high-risk group (n = 150) will consist of women with at least one episode of MDD since their baby's birth. * To qualify for the low-risk group (n = 75), women cannot have a history of any depressive disorder or any current psychiatric diagnoses. * Infants will be required to be singleton children born full-term (\> 37 weeks) and normal weight (\> 2,500 grams) with no birth complications or health problems to avoid medical complications contributing to infants' attention, reactivity, and regulation measures. * The two groups will be matched on demographic factors (e.g., age, race/ethnicity, income). Exclusion Criteria: * Additional exclusion criteria are diagnoses of alcohol or substance use disorders currently or at any point during pregnancy, or lifetime history of bipolar or psychotic disorders.
Conditions Diabetes, Diabetic Polyneuropathy
Phase Not Applicable
Enrollment 86
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to quantitatively evaluate ultrasonographic measurements of the lower extremity nerves in patients diagnosed with diabetic polyneuropathy and to investigate the relationship with gait, static and dynamic balance performance. In this study, we aimed to investigate the effect of ultrasonographic findings of lower extremity nerves on quality of daily life, physical activity, gait and balance in patients with diabetic peripheral polyneuropathy.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Ultrasonography — Measurements will be performed using a 7-12 MHz Sonosite M-Turbo device (Fujifilm, USA) with a linear probe by an operator trained in peripheral nervous system ultrasonography. Cross-sectional area (CSA) and echogenicity measurements of the bilateral tibial, common peroneal, and sural nerves will be conducted using the ultrasound device. Tibial nerve assessment will be performed 3 cm proximal to the level of the medial malleolus. Common peroneal nerve assessment will be performed by identifying the nerve at the fibular head and tracking it proximally to image it at the level of the popliteal fossa. Sural nerve assessment will be conducted 10 cm proximal to the upper level of the lateral malleolus. All nerve measurements will be conducted twice in the transverse plane, and the obtained images will be recorded and uploaded into the ImageJ programming system.
  • Diagnostic Test: Biodex Balance System — The Biodex is a computer-assisted device with a movement system capable of providing surface inclinations ranging from 360 degrees to 20 degrees. It allows movement in anterior/posterior and mediolateral planes. The device has 12 levels of difficulty, where level 12 represents the highest stability and level 1 represents the lowest stability. It can be used for balance training with different therapy protocols and includes standardized programming systems for evaluating both static and dynamic balance. It provides numerical data for key parameters such as balance, fall risk, and proprioception. In this study, patients will be assessed using the fall risk test and postural stability evaluation test protocols on the Biodex balance system. All participants will be trained and familiarized with the system before the test. Postural Stability Test: The difficulty level will be set to 8. Fall Risk Test: The difficulty level will progressively decrease from 6 to 2.
  • Diagnostic Test: Douleur Neuropathique 4 (DN4) Pain Scale — The Douleur Neuropathique 4 (DN4) pain scale score will be used to screen for diabetic peripheral neuropathic pain. The DN4 scale consists of 10 questions, 7 of which inquire about symptoms, and 3 that assess the patient's clinical examination for neuropathy. The symptoms assessed include a burning sensation, pain from cold, electric shock sensations, tingling, pins and needles, numbness, and itching. The sensory exams assess touch hypoesthesia, pin-prick hypoesthesia, and brush allodynia. Each "yes" response to a question receives 1 point. To calculate the total score, points obtained from the symptom inquiry and clinical examination are added together. The maximum total score is 10, and a score of 4 or higher is considered indicative of neuropathic pain
  • Diagnostic Test: Numeric Rating Scale — The numeric pain scale will be used to assess the intensity of neuropathic pain. The patient is asked to provide a value between 0 and 10 to indicate the intensity of their pain. Higher scores are associated with an increase in pain severity.
  • Diagnostic Test: Toronto Clinical Neuropathy Score — The Toronto Clinical Neuropathy Score (TCNS) will be used to assess the severity of Diabetic Peripheral Polyneuropathy (DPPN). The Turkish version of the Toronto clinical scoring system is a reliable and valid tool for assessing polyneuropathy in Turkish-speaking patients. The TCNS is preferred in clinical studies because of its ease of use, patient acceptability, ability to classify the severity of DPPN, and its representation of clinical changes related to the progression of DPPN. The scale consists of three sections: symptom scores, sensory test scores, and reflex scores.The first section includes scoring symptoms in the upper and lower extremities .The second section includes scoring the bilateral Achilles and patellar reflexes. The third section involves scoring the sensation in the toe. The total score ranges from a minimum of 0 (no neuropathy) to a maximum of 19 points.
  • Diagnostic Test: Six-Minute Walk Test — Six-Minute Walk Test (6MWT) is a commonly used test to assess functional capacity. The test area should be a corridor with a minimum length of 30 meters, flat, and firm surface. The corridor should be marked every 3 meters. Turnaround points are indicated with objects such as orange traffic cones. A line is drawn for the start and end of the test. Recommended materials for the test include a stopwatch, a device to count laps, cones to mark turning points, a chair placed within easy reach, oxygen support (to be given if necessary), and a blood pressure cuff. The patient should wear comfortable clothing and shoes suitable for walking. They can use any walking aids such as crutches or a walker. Medications or treatments should be taken as usual. The patient should have had a light meal before the test and should not have engaged in heavy physical activity within the 2 hours preceding the test. There should be no warm-up period before the test.
  • Diagnostic Test: SF-12 Quality of Life Scale — The SF-12 Quality of Life Scale will be calculated using an online calculator tool, providing two types of scores: physical and mental scores.
  • Combination Product: International Physical Activity Questionnaire-Short Form (IPAQ) — The IPAQ scale was developed to address the general health problem of insufficient physical activity, which necessitates large population studies and allows for cross-country comparisons. Validity studies conducted across multiple countries have proven that this questionnaire is valid and reliable. This survey assesses individuals based on the types of physical activities they perform in their daily lives. The questions asked pertain to the time spent physically active over the past 7 days.

Primary Outcomes

  • Ultrasonography (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2025-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Principal Investigators:
  • Emre Ata, Ass. Prof. (STUDY_DIRECTOR) - Sultan 2. Abdulhamid Han Training and Research Hospital
  • Feyza Nur Yücel, Specialist (STUDY_DIRECTOR) - Sultan 2. Abdulhamid Han Training and Research Hospital
  • Semiha Özgüç, M.D. (PRINCIPAL_INVESTIGATOR) - Sultan 2. Abdulhamid Han Training and Research Hospital
Contact Information
Study Contact:
Semiha Özgüç
5426311029
semihaozguc@hotmail.com
semiha özgüç acar, doctor
5426311029
semihaozguc@hotmail.com
Sultan 2. Abdulhamid Han Training and Research Hospital
Interventions
  • Diagnostic Test: Ultrasonography — Measurements will be performed using a 7-12 MHz Sonosite M-Turbo device (Fujifilm, USA) with a linear probe by an operator trained in peripheral nervous system ultrasonography. Cross-sectional area (CSA) and echogenicity measurements of the bilateral tibial, common peroneal, and sural nerves will be conducted using the ultrasound device. Tibial nerve assessment will be performed 3 cm proximal to the level of the medial malleolus. Common peroneal nerve assessment will be performed by identifying the nerve at the fibular head and tracking it proximally to image it at the level of the popliteal fossa. Sural nerve assessment will be conducted 10 cm proximal to the upper level of the lateral malleolus. All nerve measurements will be conducted twice in the transverse plane, and the obtained images will be recorded and uploaded into the ImageJ programming system.
  • Diagnostic Test: Biodex Balance System — The Biodex is a computer-assisted device with a movement system capable of providing surface inclinations ranging from 360 degrees to 20 degrees. It allows movement in anterior/posterior and mediolateral planes. The device has 12 levels of difficulty, where level 12 represents the highest stability and level 1 represents the lowest stability. It can be used for balance training with different therapy protocols and includes standardized programming systems for evaluating both static and dynamic balance. It provides numerical data for key parameters such as balance, fall risk, and proprioception. In this study, patients will be assessed using the fall risk test and postural stability evaluation test protocols on the Biodex balance system. All participants will be trained and familiarized with the system before the test. Postural Stability Test: The difficulty level will be set to 8. Fall Risk Test: The difficulty level will progressively decrease from 6 to 2.
  • Diagnostic Test: Douleur Neuropathique 4 (DN4) Pain Scale — The Douleur Neuropathique 4 (DN4) pain scale score will be used to screen for diabetic peripheral neuropathic pain. The DN4 scale consists of 10 questions, 7 of which inquire about symptoms, and 3 that assess the patient's clinical examination for neuropathy. The symptoms assessed include a burning sensation, pain from cold, electric shock sensations, tingling, pins and needles, numbness, and itching. The sensory exams assess touch hypoesthesia, pin-prick hypoesthesia, and brush allodynia. Each "yes" response to a question receives 1 point. To calculate the total score, points obtained from the symptom inquiry and clinical examination are added together. The maximum total score is 10, and a score of 4 or higher is considered indicative of neuropathic pain
  • Diagnostic Test: Numeric Rating Scale — The numeric pain scale will be used to assess the intensity of neuropathic pain. The patient is asked to provide a value between 0 and 10 to indicate the intensity of their pain. Higher scores are associated with an increase in pain severity.
  • Diagnostic Test: Toronto Clinical Neuropathy Score — The Toronto Clinical Neuropathy Score (TCNS) will be used to assess the severity of Diabetic Peripheral Polyneuropathy (DPPN). The Turkish version of the Toronto clinical scoring system is a reliable and valid tool for assessing polyneuropathy in Turkish-speaking patients. The TCNS is preferred in clinical studies because of its ease of use, patient acceptability, ability to classify the severity of DPPN, and its representation of clinical changes related to the progression of DPPN. The scale consists of three sections: symptom scores, sensory test scores, and reflex scores.The first section includes scoring symptoms in the upper and lower extremities .The second section includes scoring the bilateral Achilles and patellar reflexes. The third section involves scoring the sensation in the toe. The total score ranges from a minimum of 0 (no neuropathy) to a maximum of 19 points.
Study Locations (2 sites)
Sultan 2. Abdulhamid Han Training and Research Hospital, Istanbul, Üsküdar 34674 Turkey (Türkiye)
Sultan 2. Abdulhamid Han Training and Research Hospital, Istanbul, Üsküdar Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria (Group 1): * Being between the ages of 18-65 * Being literate * Signed a voluntary consent form agreeing to participate in the study Inclusion Criteria (Group 2): * Diagnosed with Type 2 Diabetes based on at least one of the following diagnostic criteria: fasting plasma glucose ≥ 126 mg/dl, 2-hour plasma glucose ≥ 200 mg/dl in an oral glucose tolerance test, HbA1c ≥ 6.5%, or diabetes symptoms (excessive thirst, eating, urination, and weight loss) + random plasma glucose ≥ 200 mg/dl. (14) * Diagnosed with diabetic peripheral polyneuropathy through EMG evaluation in addition to Type 2 Diabetes. * Being between the ages of 18-65 * Being literate * Signed a voluntary consent form agreeing to participate in the study. Exclusion Criteria: * Individuals under 18 years old and over 65 years old * Diagnosed with Type 1 diabetes * Use of medications that can cause polyneuropathy * Other causes of neuropathic pain (lumbar radiculopathy, spinal stenosis, -hereditary, inflammatory, entrapment neuropathies) * Undergoing lower extremity surgery (spine/hip/knee/foot) in the last 6 months * Having peripheral artery disease * B12 vitamin deficiency * Active foot ulcer * History of lower extremity amputation * Severe cardiopulmonary insufficiency (stage 3-4) * History of myocardial infarction within the last 1 month * History of unstable angina * Active systemic inflammatory diseases and active malignancy * Presence of vestibular disorders * Presence of cognitive impairment * Osteoarthritis in the lower extremity * Pregnancy * Body Mass Index (BMI) of 30 or higher
Conditions Depressive Symptoms, Generalized Anxiety...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the effectiveness of the CAMMA intervention in reducing psychological distress among family caregivers of adults with chronic conditions in Thailand. Psychological distress is operationalized as depressive symptoms, anxiety symptoms, and perceived stress.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Quadruple

Interventions / Regimen

  • Behavioral: Caregiver Mental Health Mobile Application (CAMMA) Intervention — 12-week system-integrated digital intervention including caregiver-facing mental health self-monitoring tools, self-care and caregiving support modules, facilitated peer interaction, and standardized triage/referral workflows supported by Care Manager / Community Caregiver digital interfaces. Engagement prompts and monitoring dashboards are used to support sustained use.
  • Behavioral: Usual Care Group — 12-week enhanced usual care including general health education materials and facilitated group discussions; no access to CAMMA's caregiver mental health monitoring, caregiver-specific self-care module

Primary Outcomes

  • Depressive Symptoms (At baseline (during about 2 weeks after consent and prior to initiation of study condition procedures), post-intervention (at the conclusion of the 12-week intervention period), and follow-up (approximately 3 months after completion of the intervention))
  • Anxiety Symptoms (At baseline (during about 2 weeks after consent and prior to initiation of study condition procedures), post-intervention (at the conclusion of the 12-week intervention period), and follow-up (approximately 3 months after completion of the intervention))
  • Perceived Stress (At baseline (during about 2 weeks after consent and prior to initiation of study condition procedures), post-intervention (at the conclusion of the 12-week intervention period), and follow-up (approximately 3 months after completion of the intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2028-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Hongtu Chen, PhD
617 459 5072
hchen@bwh.harvard.edu
Komatra Chuengsatiansup, MD
+66 626016116
loxlix@gmail.com
Ministry of Public Health
Siranee Sihapark, PhD
+66 810551215
daosiam@gmail.com
Ministry of Public Health
Interventions
  • Behavioral: Caregiver Mental Health Mobile Application (CAMMA) Intervention — 12-week system-integrated digital intervention including caregiver-facing mental health self-monitoring tools, self-care and caregiving support modules, facilitated peer interaction, and standardized triage/referral workflows supported by Care Manager / Community Caregiver digital interfaces. Engagement prompts and monitoring dashboards are used to support sustained use.
  • Behavioral: Usual Care Group — 12-week enhanced usual care including general health education materials and facilitated group discussions; no access to CAMMA's caregiver mental health monitoring, caregiver-specific self-care module
Study Locations (1 sites)
Ministry of Public Health, Bangkok, Thailand
Eligibility Criteria
Inclusion Criteria: 1. Adult (age 18 +) family caregiver (CG) 2. Has a minimum of 4 months of experience as a caregiver and provides at least 4 hours a day of care to the care recipient (CR); 3. Access to a mobile device with internet access Exclusion Criteria: * Caregiver who refuses to provide informed consent
Conditions Treatment Resistant Depression (TRD), In...
Phase NA
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomized controlled trial with a duration of 12 weeks (4 weeks of intervention + 8 weeks of follow-up). The participants are patients with treatment-resistant depression (TRD) and high inflammatory activity (n=52). The study aims to clarify the effectiveness of 15mA, 77.5Hz transcranial alternating current stimulation (tACS) in treating TRD with high inflammatory activity by comparing the changes in depressive symptoms and biological markers after active tACS stimulation versus sham stimulation. Additionally, the study seeks to explore potential underlying mechanisms of action.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: transcranial Alternating Current Stimulation (tACS) — tACS, parameters: 15mA、77.5Hz tACS, 20 times (5 times a week, four weeks totally)
  • Device: Sham stimulation — Sham stimulation, matched with real tACS, except for providing electrical stimulation

Primary Outcomes

  • the change in scores of HAMD-17 after treatment (4 weeks (at the end week 4))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Anding Hospital
Contact Information
Study Contact:
Chenghao Yang, PhD
0086-022-88188299
yangchh@tjmhc.com
Interventions
  • Device: transcranial Alternating Current Stimulation (tACS) — tACS, parameters: 15mA、77.5Hz tACS, 20 times (5 times a week, four weeks totally)
  • Device: Sham stimulation — Sham stimulation, matched with real tACS, except for providing electrical stimulation
Study Locations (1 sites)
The 20th ward of general psychiatric department, Tianjin, Tianjin Municipality 300000 China
Eligibility Criteria
Inclusion Criteria: * (1) Aged between 18 and 55 years; (2) Diagnosed with depression through a structured clinical interview by a psychiatrist using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); (3) A total score of 17 or above on the 17-item Hamilton Depression Rating Scale (HAMD-17), with a score of 2 or more on item 1 (depression); (4) CRP level between 0.85-10 mg/L; (5) DM-TRD score of at least 12.5; (6) Stable use of treatment medications (antidepressants, antipsychotics) for at least 2 weeks during the current depressive episode; (7) Able to understand and sign the informed consent form. Exclusion Criteria: * (1) A history of current or past seizures, epilepsy, hydrocephalus, central nervous system tumors, or acute brain injury and infections; (2) A score of 3 or 4 on item 3 of the HAMD-17, or a history of suicidal behavior with significant suicide risk; (3) Received electroconvulsive therapy (ECT), modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), tACS, or other neuromodulation treatments within one month prior to enrollment; (4) Pregnant or breastfeeding women; (5) Patients with any severe organic disease or in an unstable condition due to organic disease; (6) Used anti-inflammatory drugs for more than 7 days cumulatively in the last 2 months, or used immunosuppressive drugs, such as corticosteroids; (7) Suffering from chronic infectious or autoimmune diseases, such as lupus, enteritis, hepatitis, etc.; (8) A history of substance dependence or substance abuse.
Conditions Extubation, Respiratory Depression, Acup...
Phase NA
Enrollment 236
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to investigate the effect of combined acupoint electrical stimulation at Taiyuan (LU9) and Hegu (LI4) on improving the incidence of respiratory adverse events after extubation in patients during the recovery period from general anesthesia. The main content of this study involves selecting patients who have undergone general anesthesia and are admitted to the Post Anesthesia Care Unit (PACU), with an expected 236 participants. The researchers will randomly assign participants to either the TEAS group or the control group using a random number table. In the TEAS group, electrodes will be applied to the upper limbs at the Taiyuan and Hegu acupoints, without intravenous infusion, and connected to a stimulation device. The stimulation will use a frequency of 2/100 Hz with sparse-dense waves, and the intensity will be adjusted to the maximum current that the patient can tolerate, starting at the time of extubation and continuing for 30 minutes. The control group will receive routine care. Throughout the process, no invasive procedures will be performed. In the PACU, the participants will: Be positioned in a 30° head-up tilt position, with continuous ECG monitoring. The SpO2 alarm on the monitor will be set to 95%. The same anesthesiologist will perform extubation according to the extubation criteria. After extubation, participants will receive routine oxygen therapy via a nasal cannula at 3L/min with a CO2 end-expiratory monitoring module attached to the other end of the cannula. Simultaneously, the TEAS group will undergo transcutaneous electrical stimulation for 30 minutes, or the control group will receive routine care. Participants will be observed in the PACU for at least 30 minutes. If no adverse events occur and the Steward score is ≥4, the patient will be deemed ready for discharge and escorted back to the ward. If there is any significant change in the patient's condition, they will be transferred to the ICU . If any respiratory-related adverse events occur, measures such as awakening the patient, supporting the jaw, increasing oxygen flow, or administering mask oxygen will be taken to ensure patient safety, and these events will be recorded in the "PACU Postoperative General Anesthesia Patient Condition Observation and Nursing Record."

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Transcutaneous electrical acupoint stimulation — In this study, the traditional acupoints Taiyuan (LU9) on the lung meridian and Hegu (LI4) on the large intestine meridian were selected. The lung and large intestine meridians are interconnected, so the combined application of Taiyuan and Hegu acupoints with TEAS can produce a synergistic effect. This combination enhances the replenishment of lung qi, promotes the flow of meridians, regulates qi, and disseminates lung functions. It can stimulate effective breathing in patients, thus positively influencing the improvement of their oxygen saturation levels.
  • Other: Conventional care plan — Conventional care plan

Primary Outcomes

  • Respiratory adverse events (After the patient enters the PACU from general anesthesia)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-25
Completion: 2025-12-25
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 236 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanjing First Hospital, Nanjing Medical University
Principal Investigators:
  • xiaoliang wang (STUDY_DIRECTOR) - The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
hua guan
+8618951670974
821278639@qq.com
zhang ying, Master degree
86+15380998716
1070434273@qq.com
Nanjing First Hospital
wang xiao liang, Doctor
86+13776615743
Nanjing First Hospital
Interventions
  • Other: Transcutaneous electrical acupoint stimulation — In this study, the traditional acupoints Taiyuan (LU9) on the lung meridian and Hegu (LI4) on the large intestine meridian were selected. The lung and large intestine meridians are interconnected, so the combined application of Taiyuan and Hegu acupoints with TEAS can produce a synergistic effect. This combination enhances the replenishment of lung qi, promotes the flow of meridians, regulates qi, and disseminates lung functions. It can stimulate effective breathing in patients, thus positively influencing the improvement of their oxygen saturation levels.
  • Other: Conventional care plan — Conventional care plan
Study Locations (2 sites)
Nanjing First Hospital, Nanjing, Jiangsu 210006 China
Nanjing First Hospital, Nanjing, Jiangsu 221006 China
Eligibility Criteria
Inclusion Criteria: * 1: Age \>18 years old. 2: ASA I-III 3: Patients undergoing elective general anesthesia surgery who are extubated upon arrival to the PACU Exclusion Criteria: * 1: Preoperative comorbidities include severe cardiovascular or respiratory diseases 2: Serious reflux aspiration during the perioperative period 3: Concurrent psychiatric disorders 4: Local skin infections or nerve damage at the upper limb Taiyuan and Hegu acupoints
Conditions Advanced Solid Tumors
Phase PHASE1, PHASE2
Enrollment 156
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, open-label, single-arm, dose-escalation and dose-expansion Phase I/II study to evaluate the safety, tolerability and preliminary anti-tumor activity of MB0151 in adult subjects (at least 18 years old) with advanced solid tumors. This study includes two phases: dose escalation and dose expansion. In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation,administered intravenously every 2 weeks. Enrolled subjects will be sequentially assigned to the planned dose cohorts according to this protocol to receive MB0151 treatment and will be monitored for the occurrence of DLT. The RP2D and/or OBD will be determined by considering the PK profile, safety and efficacy data in the dose-escalation stage (including backfill cohorts).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MB0151 for injection — In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation. administered intravenously every 2 weeks .

Primary Outcomes

  • Phase I: Incidence of AEs, SAEs, infusion-related AEs, administration site AEs, AEs with CTCAE Grade ≥ 3 and AEs related to the investigational product (up to 2 years)
  • Phase I: Incidence of DLT, MTD (From the first dose to 28 days)
  • Phase I: ECG QTc Interval (up to 2 years)
  • Phase I: OBD for dose-expansion study (up to 2 years)
  • Phase II: ORR (up to 2 years)
  • Phase II: DOR (up to 2 years)
  • Phase II: DCR (up to 2 years)
  • Phase II: PFS (up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-05-08
Completion: 2028-07-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mainline Biosciences (Shanghai) Co., Ltd
Contact Information
Study Contact:
Jinming Yu, Doctor of Medicine
13806406293
sdyujinming@126.com
Yuping Sun, Doctor of Medicine
13370582181
13370582181@163.com
Jinming Yu
13806406293
sdyujinming@126.com
Cancer Hospital Affiliated to Shandong First Medical University
Interventions
  • Drug: MB0151 for injection — In this study, the protocol of accelerated titration combined with i3+3 is used for dose escalation. administered intravenously every 2 weeks .
Study Locations (1 sites)
Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250117 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female subjects over 18 years of age. 2. The subject must have a solid tumor confirmed by histology or cytology, and belong to one of the following categories: 1) locally advanced or metastatic SCLC, which has received standard treatment in the past and developed progress or intolerance; 2) Low-grade, medium-grade or high-grade locally advanced or metastatic GEP-NET, who has previously received first-line or multi-line anti-tumor treatment and developed progress or intolerance (unless there is no standard treatment available or such treatment is not suitable); 3) Metastatic or locally advanced unresectable TNBC, which is confirmed by histological examination, is characterized by the lack of expression of human epidermal growth factor 2(HER2), estrogen receptor (ER) and progesterone receptor (PR), and recurs/is refractory after standard treatment or has no standard treatment (which must include paclitaxel chemotherapy). 4) Other locally advanced or metastatic solid tumor subjects who have failed or are intolerant of standard treatment. 3. ECOG PS is 0-1. 4. Life expectancy ≥3 months. 5. Organ function is normal, which is defined as follows: 1) Bone marrow (not treated with blood transfusion or hematopoietic stimulating factors within 14 days): absolute neutrophil (ANC) ≥ 1.5× 10 9/L, platelet count ≥ 100× 10 9/L, hemoglobin ≥ 90 g/L. 2) Liver: total bilirubin (TBIL) ≤1.5× upper limit of normal value (ULN), or TBIL\>1.5×ULN with direct bilirubin (DBIL) ≤ ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤3×ULN (≤5×ULN if accompanied by liver metastasis). 3) Kidney: serum creatinine concentration ≤1.5×ULN or creatinine clearance ≥50 mL/min(Cockcroft-Gault formula) 4) Coagulation function: partial thromboplastin activation time (APTT) or ≤ 1.5× ULN; International normalized ratio (INR) or prothrombin time (PT)≤1.5×ULN (INR\<3.0 if the subject uses anticoagulant). 6. Detection requirements for biomarkers: 1) For the dose escalation and backfill cohort in Phase I study, biomarkers are not detected when they are selected, and the subjects need to provide archived or fresh tumor tissues within 2 years (if the archived tissue samples are more than 2 years and fresh tumor tissues are difficult to obtain, they can communicate with the applicant to decide whether to exempt them); During the study, the biomarker detection results of subjects in the follow-up dose expansion cohort may be added as additional selection criteria according to the obtained clinical data; 2) For Phase II study, the subjects should provide archived or fresh tumor tissues within 2 years (if the archived tissue samples are more than 2 years and fresh tumor tissues are difficult to obtain, they can communicate with the sponsor to decide whether to exempt them), and at baseline, the biomarkers should be detected by IHC in the central laboratory. 7. According to the RECIST version 1.1 standard, there is at least one target lesion (the target lesion must have not received radiotherapy before, or there is clear evidence of disease progression after radiotherapy). 8. Male or female subjects who are infertile, not in pregnancy or agree to use at least one effective contraceptive method during the study intervention period (from 14 days before the first administration to at least 180 days after the last administration of the study intervention) are eligible to participate in the study, and abide by the following contents: 1) Avoid donating fresh unwashed sperm or eggs. 2) Women who are breastfeeding should stop breastfeeding during the study period. 9. An informed consent form (ICF) that can be understood and signed, including compliance with ICF and the requirements and restrictions listed in this plan. Exclusion Criteria: 1. According to the researcher's judgment, there are serious or poorly controlled systemic diseases, active bleeding tendency, renal transplantation or liver transplantation, active infection, including syphilis-specific antibody or human immunodeficiency virus (HIV) antibody positive, or active hepatitis B (hepatitis B surface antigen positive and/or core antibody positive and HBV-DNA copy number \> 1000 copies /ml or \> 200 IU/ml) or hepatitis C (C). 2. Suffering from other malignant tumors within 3 years before the first administration, except those who have received adequate treatment: 1) Cervical cancer in stage 1B or below. 2) Non-invasive basal cell or squamous cell skin cancer. 3) Non-invasive superficial bladder cancer. 4) Prostate cancer, the current PSA level is less than 0.1 ng/ mL. 3. Meet one or more of the following cardiac criteria: 1) Severe or unstable angina pectoris; 2) Myocardial infarction, coronary artery or peripheral artery bypass grafting, stroke or transient ischemic attack and symptomatic orthostatic hypotension occurred within 6 months before screening; 3) new york Heart Association II-IV heart failure; 4) QT interval (QTc) corrected by Fredericia formula at baseline: male \> 450 msec, female \> 470 msec;; 5) There are serious abnormalities in heart rhythm, conduction or morphology (for example, complete left bundle branch block, third degree heart block); 6) Congenital long QT syndrome; 7) Hypertension that is still poorly controlled after antihypertensive treatment (it needs to be measured three times continuously, that is, systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg). 4. Received major surgery within 28 days before C1D1. 5. There are unstable brain metastases with clinical symptoms and/or a history of meningeal diseases, brain stem or spinal cord compression. Subjects who have no clinical symptoms and have ≤3 metastatic lesions, and the largest lesion diameter is \< \<0.5cm, or whose symptoms are stable after treatment and do not need hormone drugs, can enter the study if they meet all the following criteria: (1) There are other measurable lesions besides the central nervous system; (2) New or expanded metastatic foci that have been in a stable state for at least 4 weeks without clinical evidence. If whole brain radiotherapy has been performed, it is at least 28 days before the first administration; If it is stereotactic radiosurgery or stereotactic radiotherapy, it is at least 14 days before the first administration. 6. Have a life-threatening trauma with increased risk of bleeding or a history of severe head trauma or intracranial surgery within 2 months before enrollment. 7. There is clear imaging evidence of tumor cavity or large blood vessel invasion, and the tumor is adjacent to important blood vessel structures, and the researcher judges that there is a risk of fatal bleeding. 8. Peripheral motor neuropathy or peripheral neuropathy with CTCAE grade ≥2 exists. 9. There are active viral, bacterial or fungal infections with clinical significance, which need the following treatment: 1) start intravenous antibacterial treatment within 4 weeks before the first administration, or 2) start oral antibacterial treatment within 10 days before the first administration. 10. Suffering from inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. 11. Pneumonia ≥ 3 or clinically significant lung diseases, such as interstitial lung disease, non-infectious pneumonia, radiation pneumonia, pulmonary fibrosis, acute lung injury, etc.; Moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring long-term drug treatment. 12 suffering from acute or chronic inflammatory skin diseases that have not yet recovered. 13\. Have a history of deep venous thrombosis, pulmonary embolism or other serious venous thromboembolism within 3 months before the first administration (implantable venous access or catheter-derived thrombosis or superficial venous thrombosis is not considered as serious venous thromboembolism). 14\. There is pelvic cavity, abdominal cavity, chest cavity or pericardial effusion that needs intervention, which can be
Conditions Breast Cancer
Phase NA
Enrollment 348
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study is a single-center, prospective, non-randomized controlled study. The primary objective is to examine the clinical outcomes of utilizing Deep Inspiration Breath Hold (DIBH) in conjunction with hypo-fractionated radiotherapy for patients diagnosed with left-sided breast cancer with a particular focus on its potential to reduce the incidence of cardiac-related clinical and subclinical events.Participants will revieve large segmentation sadiotherapy ± DIBH for left breast cancer and be followed up to gather their clinical cardiac imformation.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Large Segmentation Radiotherapy — Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
  • Device: DIBH — Deep Inspiration Breath Hold
  • Device: Surface guided radiation therapy — The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
  • Device: laser alignment — Laser systems for virtual simulation and patient positioning in radiotherapy
  • Behavioral: free breathing — Patients breathe calmly while radiotherapy instead of holding their breath.

Primary Outcomes

  • Incidence of subclinical and clinical cardiac events (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-21
Completion: 2034-08-21
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 348 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Contact Information
Study Contact:
Xiaorong Hou
+86 13811963013
hxr_pumch@163.com
Xiaorong Hou
+86 13811963013
hxr_pumch@163.com
Peking Union Medical College Hospital
Interventions
  • Radiation: Large Segmentation Radiotherapy — Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
  • Device: DIBH — Deep Inspiration Breath Hold
  • Device: Surface guided radiation therapy — The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
  • Device: laser alignment — Laser systems for virtual simulation and patient positioning in radiotherapy
  • Behavioral: free breathing — Patients breathe calmly while radiotherapy instead of holding their breath.
Study Locations (1 sites)
Peking Union Medical College Hospital, Beijing, Beijing Municipality 100730 China
Eligibility Criteria
Inclusion Criteria: 1. 18-70 years old, female, life expectancy \> 5 years 2. ECOG 0, 1, 2 points 3. Pathologically diagnosed with left breast cancer and underwent breast-conserving surgery or modified radical mastectomy 4. The patient will receive radiation therapy to the entire breast or chest wall ± the lymphatic drainage area above and below the clavicle ± the lymphatic drainage area in the axilla. 5. No prior neoadjuvant chemotherapy or breast reconstruction. 6. No active cardiac disease, myocardial infarction, or congestive cardiac failure at baseline. 7. Patients can hold their breath for at least 30 seconds after training 8. Patients who can be followed up and agree to follow the plan. 9. Sign the consent form. Exclusion Criteria: 1. Lesions were observed on both sides of the breast. 2. Diagnosis could not be confirmed by pathology. 3. Distant metastasis was identified. 4. The patient had undergone neoadjuvant chemotherapy or breast reconstruction surgery. 5. Severe cardiac insufficiency; myocardial infarction or uncorrected unstable cardiac arrhythmia or uncorrected unstable angina within the last 3 months; or pericardial disorders 6. The patient's New York Heart Association (NYHA) cardiac classification is within categories 2-4. 7. A history of chronic lung disease, including conditions that may contribute to ductal dilatation, such as chronic obstructive pulmonary disease (COPD) and interstitial pneumonia. 8. Previous mediastinal radiotherapy. 9. Previous or concurrent second primary malignant tumor (except skin cancer that is not a malignant black pigmented tumor, papillary/follicular carcinoma of the thyroid, carcinoma in situ of the cervix, and contralateral non-invasive breast cancer). 10. Irradiation of the lymphatic drainage area of the internal breast is required.
Conditions Solid Tumor, Adult, Metastatic Breast Ca...
Phase PHASE1
Enrollment 392
Locations 44 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BBO-10203 — Participants will receive assigned dose of BBO-10203 orally once daily
  • Drug: Trastuzumab — Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
  • Drug: Fulvestrant — Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
  • Drug: Ribociclib — Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
  • Drug: FOLFOX — Patients will receive FOLFOX as infusion every 14 days
  • Drug: Bevacizumab — Patients will receive bevacizumab as infusion every 28 days

Primary Outcomes

  • Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BBO-10203 as a single agent (Up to approximately 5 years)
  • Percentage of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) (Up to approximately 5 years)
  • Recommended BBO-10203 dose in combination with trastuzumab, fulvestrant +/- ribociclib, and FOLFOX + bevacizumab (Up to approximately 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-29
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 392 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Contact Information
Study Contact:
BBOT (BridgeBio Oncology Therapeutics)
650-405-8440
Breaker-101ct.gov@bridgebiooncology.com
Interventions
  • Drug: BBO-10203 — Participants will receive assigned dose of BBO-10203 orally once daily
  • Drug: Trastuzumab — Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
  • Drug: Fulvestrant — Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
  • Drug: Ribociclib — Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
  • Drug: FOLFOX — Patients will receive FOLFOX as infusion every 14 days
Study Locations (44 sites)
City of Hope Comprehensive Cancer Center, Duarte, California 91010 United States
University of California Los Angeles, Los Angeles, California 90095 United States
University of California San Diego Moores Cancer Center, San Diego, California 92093 United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94158 United States
Moffitt Cancer Center, Tampa, Florida 33612 United States
Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana 46202 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Dana-Farber Cancer Insitute, Boston, Massachusetts 02215 United States
St. Lukes Hospital of Kansas City, Kansas City, Missouri 64111 United States
Washington University School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Locally advanced and unresectable or metastatic HER2-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aNSCLC) * Measurable disease by RECIST v1.1 (except for HR-positive HER2-negative aBC where evaluable bone-only disease is permitted) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Adequate LVEF assessed by ECHO or MUGA (BBO-10203 + Trastuzumab cohorts only) * Stable brain metastases * Patients with HER2-positive aBC: Must have had at least 2 prior lines of anti-HER2-directed therapy. Only 1 prior line is acceptable where there is no other regionally available standard of care (SoC) * Monotherapy Cohort patients with HR-positive, HER2-negative aBC, KRAS mutant aCRC or aNSCLC: Must have progression on, or disease recurrence after at least one line of SOC treatment or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from SoC therapy * BBO-10203 + Fulvestrant combination cohort patients with HR-positive, HER2-negative aBC: confirmed PIK3CA mutation, must have been treated with a CDK4/6i * BBO-10203 + Fulvestrant + ribociclib combination cohort patients with HR-positive, HER2-negative aBC: confirmed PIK3CA mutation, no prior systemic therapy in the aBC setting permitted * BBO-10203 + FOLFOX + Bevacizumab combination cohort patients with KRAS mutant aCRC: One prior line of irinotecan-containing therapy for locally advanced or metastatic CRC is allowed but not required Exclusion Criteria: * Patients with KRAS mutant aCRC who have KRAS G12R mutation, BRAFV600E mutation, HER2amp, or dMMR/MSI-H tumors * Patients with KRAS mutant aNSCLC who have KRAS G12R mutation, or tumors with other targetable driver mutations (eg, EGFR, anaplastic lymphoma kinase, ROS1/BRAF/RET/MET/EGFR exon20 insertion/NTRK/HER2) * Patients with untreated and/or non-stable brain metastases Other inclusion/exclusion criteria are specified in the protocol
Conditions Breast Cancer, Weight Loss
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to help make a community led weight loss program known as Take Off Pounds Sensibly (TOPS) more relevant for breast cancer survivors. This study is made up to two parts. The first part includes using focus groups to review current materials that the investigators plan to use in upcoming TOPS classes and provide feedback. Focus groups will be made up of women who are breast cancer survivors. The second part includes taking the feedback received from these focus groups and use this feedback to tailor TOPS classes for breast cancer survivors. This ClinicalTrials.gov record is specific to the second part of the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: TOPS Classes — Attend Dietician-Led Sessions

Primary Outcomes

  • Number of invitations sent through the electronic health record to get 25 individuals consented to the study (1-2 months)
  • Percentage of TOPS group session attendance (12 months)
  • Number of participants who stay in the study (3 months, 6 months, 9 months, 12 months)
  • Number of participants who transition from the initiation phase to the maintenance phase (12 months)
  • Number of participants who continue to transmit weight and BP data once they transition to the maintenance phase (9 months, 12 months)
  • Percent of Weight Loss (Up to 12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-03
Completion: 2027-09-30
Eligibility
Age: 21 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Principal Investigators:
  • Nia S Mitchell, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Nia S Mitchell, MD
833-637-8839
nia.s.mitchell@duke.edu
Nia S Mitchell, MD
833-637-8839
nia.s.mitchell@duke.edu
Duke University
Interventions
  • Other: TOPS Classes — Attend Dietician-Led Sessions
Study Locations (1 sites)
Duke University, Durham, North Carolina 27710 United States
Eligibility Criteria
Aim 2 Inclusion Criteria: * women diagnosed with breast cancer with BMI ≥ 25 kg/m2 after completion of primary therapy (surgery, radiation, adjuvant or neo-adjuvant chemotherapy). Aim 2 Exclusion Criteria: * Those whose oncology providers do not agree with their participation in a weight loss program * History of Type II Diabetes Mellitus * those participating in another weight loss program * those taking a weight loss medication * those without smart phones or internet connections or the ability to attend meetings via Zoom
Conditions Diabetes, Pre Diabetes, Hypertension, Dy...
Phase NA
Enrollment 9000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a community-based implementation program consisting of multiple components delivered by a multidisciplinary team to detect and prevent young onset diabetes with precision and value using biogenetic markers, digital tools, integrated care through public private partnership. Adults aged between 18 and 44 (inclusive) without known diabetes and with at least one risk factor for diabetes will undergo a saliva DNA and capillary blood test and complete a questionnaire. Depending on their risk levels, participants will be stratified to high risk and low risk progressors to diabetes. The high risk progressors will undergo annual oral glucose tolerance test to detect diabetes and impaired glucose tolerance (IGT). All participants will receive a personalized report indicating their genetic and modifiable risk explained by nurses or doctors. All participants will be offered regular access to webinars for education and empowerment for 2 years. The high risk group will additionally receive a 2-year risk-stratified intervention with different combinations of care interventions. These include clinical and laboratory assessment for comprehensive evaluation of cardiovascular-kidney-metabolic risks, medical and nurse consultations, empowerment by health messages, webinars, face-to-face workshops, subsidies for medications and self-monitoring tools (e.g. CGM devices, weighing scale) to motivate behavioural change. The outcomes will be analysed within the REAIM framework (reach, effectiveness, adoption, implementation and maintenance), progresssion to prediabetes or diabetes, patient reported outcomes and cost effectiveness.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Genetic: Risk assessment with biogenetic and clinical test to predict diabetes risk — All participants will undergo genetic test and clinical measurement including body weight, body height, blood pressure, waist circumference and capillary blood glucose to predict diabetes risk with report explanation by doctors (for high risk, IGT and DM) and nurses (low risk). Genetic report will be updated annually for high risk and IGT group using updated clinical factors (e.g. age, BMI, BP).
  • Diagnostic Test: Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors — High risk progressors will undergo OGTT and measurement of CKM factors at baseline. In those without IGT or diabetes, they will undergo OGTT and CKM risk factor assessment annually for 2 years. The IGT group will additionally have measurement of beta-cell function (HOMA indexes) and the DM group will additionally have autoimmune marker measurement.
  • Drug: Medication — Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for control of glucose and CKM risk factors.
  • Device: Continuous glucose monitoring (CGM) devices and/or weighing scale — All high risk progressors will be given subsidized weighing scale and low-intensity laboratory assessments, nurse and doctor consultation, regular WhatsApp messages and webinars for 2 years. The IGT and DM group will receive additional subsidized CGM devices for empowerment.
  • Behavioral: Visit to family doctor with nurse education — All participants in high risk, IGT and diabetes groups will have regular follow-up by family doctors and nurses.
  • Diagnostic Test: Joint Asia Diabetes Evaluation (JADE) assessment — Participants found to have diabetes on OGTT will undergo annual JADE assessment which include eye/foot/urine/blood tests with issue of a personalized JADE report. The JADE Program is a quality improvement program to improve self management and inform shared decision making between doctor and patient.
  • Behavioral: Education webinars, workshops and health messages — All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.

Primary Outcomes

  • Incidence of prediabetes or diabetes in the high and low risk progressor groups (From the date of recruitment until the end of the programme in 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-23
Completion: 2028-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 9000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Juliana CN Chan
Collaborators: Chinese University of Hong Kong, St. James' Settlement, Asia Diabetes Foundation
Principal Investigators:
  • Juliana CN Chan (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
Juliana CN Chan
+85226376624
jchan@cuhk.edu.hk
Amy Fu
+85226376624
afu@adf.org.hk
Amy Fu, MPH
Asia Diabetes Foundation
Interventions
  • Genetic: Risk assessment with biogenetic and clinical test to predict diabetes risk — All participants will undergo genetic test and clinical measurement including body weight, body height, blood pressure, waist circumference and capillary blood glucose to predict diabetes risk with report explanation by doctors (for high risk, IGT and DM) and nurses (low risk). Genetic report will be updated annually for high risk and IGT group using updated clinical factors (e.g. age, BMI, BP).
  • Diagnostic Test: Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors — High risk progressors will undergo OGTT and measurement of CKM factors at baseline. In those without IGT or diabetes, they will undergo OGTT and CKM risk factor assessment annually for 2 years. The IGT group will additionally have measurement of beta-cell function (HOMA indexes) and the DM group will additionally have autoimmune marker measurement.
  • Drug: Medication — Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for control of glucose and CKM risk factors.
  • Device: Continuous glucose monitoring (CGM) devices and/or weighing scale — All high risk progressors will be given subsidized weighing scale and low-intensity laboratory assessments, nurse and doctor consultation, regular WhatsApp messages and webinars for 2 years. The IGT and DM group will receive additional subsidized CGM devices for empowerment.
  • Behavioral: Visit to family doctor with nurse education — All participants in high risk, IGT and diabetes groups will have regular follow-up by family doctors and nurses.
Study Locations (1 sites)
Asia Diabetes Foundation, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 44 years old * With at least one risk factor for diabetes Exclusion Criteria: * Known history of Diabetes * With conditions considered not suitable by the project team (including illiteracy) The risk factors for diabetes include central or general obesity, family history of diabetes, smoking history, history of hypertension/ high blood glucose level/ abnormal lipid level/ vascular disease/ fatty liver, history of gestational diabetes/ polycystic ovary syndrome/ delivery of baby≥ 4kg (for women only), and less than 150mins of physical activity every week.
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 230
Locations 50 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, approximately 35 days 2. 42-day Treatment Period 3. 2-week post dose Safety Follow-up Period 4. 6-month postdose targeted safety follow-up period

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: ABX-002 — ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
  • Other: Placebo — Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.

Primary Outcomes

  • Change from Baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17) (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-20
Completion: 2026-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Autobahn Therapeutics, Inc.
Contact Information
Study Contact:
Ashlee Heldreth, MS
8582573418
clinicaltrials@autobahntx.com
Interventions
  • Drug: ABX-002 — ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
  • Other: Placebo — Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
Study Locations (50 sites)
Autobahn Site #131, Birmingham, Alabama 35294 United States
Autobahn Site #132, Chandler, Arizona 85224 United States
Autobahn Site #116, Phoenix, Arizona 85102 United States
Autobahn Site #136, Tucson, Arizona 85704 United States
Autobahn Site #150, Anaheim, California 92805 United States
Autobahn Site #113, Encino, California 91316 United States
Autobahn Site #133, Encino, California 91316 United States
Autobahn Site #124, Glendale, California 91206 United States
Autobahn Site #140, Long Beach, California 90807 United States
Autobahn Site #121, Los Alamitos, California 90720 United States
Eligibility Criteria
Inclusion Criteria: * Meets the DSM-5 criteria for Major Depressive Disorder, with a current major depressive episode duration of \> 6 weeks and ≤ 18 months. * A score of ≤ 22 (midrange mild/moderate) on the Hamilton Anxiety Rating Scale. * Montgomery-Asberg Depression Rating Scale total score of \> 24 \[indicating moderate to severe depression\] at Screening and at Baseline. * Subject is compliantly using a single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant for at least 6 weeks for their current episode of depression, with an adequate dose, and with an inadequate response as defined by the Antidepressant Treatment Response Questionnaire. The dosage of the current antidepressant must have been stable for the past 4 weeks, and the dosage and specific antidepressant used should remain the same from Screening through the end of the Follow-up Period. Exclusion Criteria: Note: History implies lifetime history, unless otherwise specified * History of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features or concomitant DSM-5 depressive disorders, bipolar I or II disorder, cyclothymic disorder, delirium, dementia, amnestic disorder, or cognitive disorder. * Current diagnosis or active symptoms within the last 2 years of obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, or eating disorder, according to DSM-5 criteria. * Primary diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder, according to DSM-5 criteria. Current or history within the last 2 years of self-injurious behavior is exclusionary. * Has failed more than 2 single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant treatments, including the current serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor, during the current depressive episode, despite an adequate dose (per Antidepressant Treatment Response Questionnaire) and duration (at least 6 weeks). * Failure to respond to triiodothyronine or thyroxine augmentation for the treatment of depression. * Started new psychotherapy or had a change in the intensity of psychotherapy within 8 weeks before Screening. * Is suicidal at Screening or Baseline * History or current evidence within previous 3 months before Screening of uncontrolled, clinically significant neurological, gastrointestinal, respiratory, renal, hepatic, immunological, hematological, or other medical disorder, including cancer, that would jeopardize the safe participation of the subject in the study (in the opinion of the Investigator). * History of thyroid disease * History of multiple endocrine neoplasia syndrome * Diagnosis of epilepsy or history of convulsions, including childhood febrile seizure. Use of co-administered drugs that may lower seizure threshold is excluded. * Females who are pregnant, intend to become pregnant or are breastfeeding. * Antidepressants: Prior use of psychedelics, ketamine, or esketamine, for the treatment of Major Depressive Disorder. * Antidepressants: Current use, or use within 4 weeks prior to Screening, of any other augmentation agents for Major Depressive Disorder (e.g. second-generation antipsychotics \[SGA\], monoamine oxidase inhibitors \[MAOI\], tricyclic antidepressants \[TCA\], lithium, or bupropion) * Current or prior use of treatment for hypothyroidism including but not limited to synthetic or natural thyroid hormone, triiodothyronine and/or thyroxine. * Concomitant use of biotin of any dose and in any preparation 14 days prior to Day 1 until after the last study visit at Week 8 (Day 56). * Medications that are strong cytochrome P450 3A4 inhibitors or strong cytochrome P450 3A4 inducers are not allowed. * Prescription drug/controlled substance abuse, or illicit substance use within 1 year of Screening or positive urine drug results at Screening or Baseline for an illicit substance. * History or presence of cataract on ophthalmic examination (including slit-lamp), glaucoma, inflammatory eye disease or prior ophthalmic surgical procedures or laser surgery in either eye
Conditions Lung Cancer, Breast Cancer
Phase PHASE1, PHASE2
Enrollment 416
Locations 65 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BMS-986507 — Specified dose on specified days
  • Drug: Osimertinib — Specified dose on specified days
  • Drug: Pembrolizumab — Specified dose on specified days
  • Drug: Nivolumab — Specified dose on specified days
  • Drug: Pumitamig — Specified dose on specified days

Primary Outcomes

  • Number of participants with adverse events (AEs) (Up to 3 years)
  • Number of participants with serious adverse events (SAEs) (Up to 3 years)
  • Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera (Up to 3 years)
  • Number of participants with AEs leading to discontinuation (Up to 3 years)
  • Number of participants with AEs leading to death (Up to 3 years)
  • Number of DLTs that occur during the DLT evaluation period (Up to 3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-02-04
Completion: 2031-02-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 416 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bristol-Myers Squibb
Principal Investigators:
  • Bristol-Myers Squibb (STUDY_DIRECTOR) - Bristol-Myers Squibb
Contact Information
Study Contact:
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Aakash Desai, Site 0066
919-525-0054
University of Alabama at Birmingham
Interventions
  • Drug: BMS-986507 — Specified dose on specified days
  • Drug: Osimertinib — Specified dose on specified days
  • Drug: Pembrolizumab — Specified dose on specified days
  • Drug: Nivolumab — Specified dose on specified days
  • Drug: Pumitamig — Specified dose on specified days
Study Locations (65 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida 33136 United States
Local Institution - 0065, Iowa City, Iowa 52242 United States
Local Institution - 0140, St Louis, Missouri 63110 United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey 07601 United States
Cleveland Clinic, Cleveland, Ohio 44195 United States
Local Institution - 0102, Columbus, Ohio 43212 United States
Providence Portland Medical Center, Portland, Oregon 97213 United States
Providence St. Vincent Medical Center, Portland, Oregon 97225 United States
Local Institution - 0052, Portland, Oregon 97239 United States
Eligibility Criteria
Inclusion Criteria * Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have a life expectancy of at least 3 months at the time of the first dose. * Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed * Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC. * Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC. * Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO/CAP criteria, based on the most recently analyzed biopsy or another pathology specimen. * Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent. Exclusion Criteria * Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology. * Participants with known mutations in EGFR will be excluded (Group A,B and E). * Participants must not have a history of serious recurrent infections. * Participants must not have a history of severe heart disease. * Other protocol-defined Inclusion/Exclusion criteria apply.